The morbidity and mortality of COPD continues to increase in the United States and worldwide 1 ; however, progress in the diagnosis and treatment of COPD remains limited. One approach to address this issue has been to screen large cohorts of patients with COPD for new biomarkers of disease severity and/or progression, 2 but the specificity and function of recently identified biomarkers (eg, fibrinogen) to the pathogenesis of COPD remain uncertain. Therefore, new biomarkers that reflect the key cellular and molecular events in COPD, such as airway mucus production and lung immune cell activation, are still needed to advance the management of patients with this type of disease.
A key insight to the development of COPD has been the role of the type 2 immune response as a critical driver for airway inflammatory disease. 3 In fact, this concept is leading to new biological therapeutics that appear effective in airway disease because of asthma. 4, 5 The rationale for this approach derives at least in part from experimental models of airway disease. In particular, a type 2 immune response that includes airway epithelial production of IL-33 to stimulate immune cell production of IL-13 and consequent airway mucus production appears critical for the development of chronic lung disease after respiratory viral infection in a mouse model of this process. 6, 7 Indeed, similar immune events (eg, IL-33 and IL-13 production, M2 macrophage activation, excess mucin formation) are also found in studies of humans with COPD. [7] [8] [9] [10] [11] [12] Most recently, experimental work by our group in a postviral mouse model of airway disease identified a key pathogenic role for another type 2 immune component known as Triggering Receptor Expressed on Myeloid Cells (TREM)-2. Previous work had identified 2 TREM proteins: TREM-1, expressed by myeloid cells (neutrophils and monocyte/macrophage lineages) and activated by lipopolysaccharide in the setting of bacterial infection, [13] [14] [15] [16] and TREM-2, confined to monocytemacrophage lineages in response to type 2 cytokines IL-4 and IL-13. 17, 18 Both TREM-1 and TREM-2 were thought to signal via the adapter protein DAP12. Although most studies of Trem-2 had focused on its function as a surface receptor in association with Dap12, our studies of the postviral mouse model of airway disease showed that IL-13 promotes cleavage of mouse Trem-2 to a soluble form that promotes M2 macrophage survival and helps to amplify type 2 inflammatory airway disease. 18 These observations were consistent with the proposed role of M2 macrophages in COPD, and the possibility that M2 biomarkers such as chitinase 1 (CHIT1), MMP12, and CD206 might be candidates for monitoring macrophage activity in this disease setting.
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Previous clinical studies of TREM-2 in humans have linked increased levels and/or activity primarily to CNS disease, 18, 20, 21 whereas only a few studies have examined TREM proteins in COPD. Increased levels of the cleaved form of TREM-1 were found in serum from patients with severe COPD. [22] [23] [24] In addition, increased TREM2 messenger RNA (mRNA) expression was observed in lung macrophages from smokers compared with nonsmokers, 25, 26 consistent with induction of TREM-2 in a macrophage cell line exposed to cigarette smoke extract. 26 However, the levels of TREM-1 and TREM-2 expression, particularly in relation to macrophage activation in COPD, remain uncertain. Here, we examined the expression of TREM-1 and TREM-2 in the context of M2 macrophage activation in lung tissue samples from nonsmokers and in a spectrum of patients who had COPD. Some of these data have been reported in abstract form. 27 
Materials and Methods

Human Lung Samples
Lung tissue samples were obtained from two cohorts at the time of lung surgery at Barnes-Jewish Hospital (St. Louis, MO 
Real-Time Polymerase Chain Reaction Assay
RNA was purified from lung homogenates using Trizol (Invitrogen) and converted to complementary DNA (cDNA) using a High-Capacity cDNA Archive kit (Applied Biosystems). Target mRNA was quantified by real-time polymerase chain reaction (PCR) assay using specific fluorogenic probes and primer sets and the Fast Universal PCR Master Mix system (Applied Biosystems). All probes were designed to span introns and did not react with genomic DNA.
Samples were assayed with the 7300HT or 7500 Fast Real-Time PCR System and analyzed using Fast System Software (Applied Biosystems) in triplicate using either 96-well or 384-well formats. Table 3 lists primer and probe sets used in these studies. In cohort 1, mRNA expression levels were calculated using ddCT, and normalized to levels of mRNA found in non-COPD donor lung tissues as reported previously. 7 In cohort 2, mRNA copy numbers were quantified based on cDNA standards.
Enzyme-Linked Immunosorbent Assays (ELISAs)
Whole lung tissues (approximately 200 mg) were digested in radioimmunoprecipitation assay (RIPA) lysis buffer, homogenized, and cleared by centrifugation. Supernatants were used for ELISA.
Immunohistochemistry
Tissues were fixed with 10% formalin, embedded in paraffin, cut into 5-mm sections, and adhered to charged slides. Sections were deparaffinized in Fisherbrand CitroSolv (Fisher), hydrated, and treated with heat-activated antigen unmasking solution (Vector Laboratories). Immunostaining was performed using anti-TREM-2 (Novus Biologicals), anti-TREM-1 (R&D), anti-CD68 (Santa Cruz), and anti-CCR2 (Biolegend) followed by biotinylated species-specific secondary antibodies. Antibody binding was detected using diaminobenzidine with tyramide-based signal amplification with Alexa Fluor 488 nm or 594 nm fluorochromes (Invitrogen) for 
a Primer/probe sets for TREM1, TREM2, and CD206/MRC1 in cohort 1 were from Applied Biosystems.
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Statistical Analyses
Mann-Whitney U test and Spearman correlations were used for comparisons between two groups. Kruskal-Wallis test with Dunn posttest correction was used for comparisons between groups of three or more. Receiver operating characteristics were used to define the sensitivity and specificity of the TREM2/TREM1 ratio to identify severe and very severe (GOLD stages III and IV) COPD. Data were analyzed and plotted using GraphPad Prism (v6.0) software (GraphPad).
Results
TREM2 mRNA Expression Is Increased in COPD
Levels of TREM2 but not TREM1 mRNA were significantly increased in lung tissue from patients with COPD (n ¼ 16) compared with non-COPD patients (n ¼ 7) in our analysis of cohort 1 (Fig 1A) . Moreover, the level of expression for TREM2 mRNA correlated closely with the TREM-2 adaptor DAP12 mRNA and the conventional macrophage marker CD68 mRNA and M2 macrophage marker CD206/ MRC1 mRNA ( Fig 1B) . The increase in TREM2 mRNA was also accompanied by a significant increase in CHIT1 mRNA in lung tissue from patients with COPD (e- Fig 1A) , consistent with our previous observations. 9 The level of TREM2/CD68 but not TREM1/CD68 was also significantly increased in lung tissue from patients with COPD compared with non-COPD (Fig 1C) , consistent with selective induction of TREM2 expression in lung macrophages vs an increase in TREM2 levels based only on macrophage accumulation in COPD.
TREM-2 Protein Expression Is Increased in COPD
Consistent with the analysis of TREM mRNA levels, the levels of TREM-2 but not TREM-1 protein were also significantly increased in lung tissue from patients with COPD vs non-COPD (Fig 2A) . In addition, the numbers of lung cells that immunostained for TREM-2 were increased compared with TREM-1. Moreover, even the detectable TREM-1-positive cells were also TREM-2-positive ( Fig 2B) . TREM-2 immunostaining was localized primarily to macrophages based on morphologic appearance and costaining with CD68, confirming the close correlation between TREM2 and CD68 mRNA in Figure 1B , and TREM-2 also overlapped with CCR2 immunostaining, consistent with the presence of activated lung tissue monocytes and macrophages in COPD. 28 TREM-2 expression was also detected on lung tissue monocytes based on forward scatter and CD14 expression detected with flow cytometry in both patients with COPD and non-COPD (Fig 2C) . Interestingly, the levels of surface TREM2 expression were similar in CD14-positive lung cells from patients with COPD and non-COPD compared with the differences in protein expression found in lung tissue lysates in Figure 2A . In contrast, TREM-1 expression was barely detectable above background in these samples. Together, these results confirm that TREM-2 expression is a robust marker of lung tissue macrophage populations in patients who have severe COPD.
TREM2 Expression Tracks With COPD Severity in a Second Cohort
To validate and extend the results from cohort 1, we also studied samples from cohort 2 that represents a broader spectrum of COPD, including never smokers (n ¼ 7), smokers at risk for COPD (n ¼ 19), and current and former smokers with GOLD stage I to IV COPD (n ¼ 29). For this second cohort, we also applied quantified TREM2 and TREM1 mRNA copy numbers in place of the semi-quantitative ddCT values used for the analysis of cohort 1. We found a significant increase in lung levels of TREM2 but not TREM1 mRNA in patients with GOLD stage 4 COPD compared with never smokers when normalized to GAPDH (Fig 3A) or CD68 (Fig 3B) . We also detected a significant correlation between lung levels of TREM2 and CD68 mRNA (Spearman r ¼ 0.714, P < .0001, data not shown).
Despite relatively low levels of TREM1 expression on cells of the myeloid lineage, we were still able to detect a significant correlation between the levels of TREM1 and TREM2 mRNA (Fig 3C) . However, the disproportionate increases in TREM2 mRNA translated into a marked increase in the ratio of TREM2 to TREM1 mRNA in patients with GOLD stage IV COPD compared with never smokers (Fig 3D) . Moreover, using receiver operating characteristics analysis, a TREM2/TREM1 ratio of $ 1.5 copies was 82% sensitive and 63% specific for predicting GOLD stage III and IV COPD, compared with never smokers and patients with GOLD stage I or II COPD (Fig 3E) . TREM2/TREM1 ratio also inversely correlated with FEV 1 and FEV 1 /FVC across the entire cohort of patients with COPD and non-COPD (Fig 3F) , similar to the correlations of CHIT1 mRNA in the present cohort (e-Figs 1B, 1C) and our previous report. 9 We also examined the relationship between TREM expression and smoking status. TREM1, TREM2, and TREM2/TREM1 levels were examined in cohort 2 samples categorized as never smokers, former smokers, or current smokers at the time of tissue collection. TREM1 and TREM2 mRNA levels were higher in lung tissues from current smokers compared with former smokers, but these levels were not significantly different between former smokers and never smokers. However, the TREM2/TREM1 ratio was significantly higher in the lung tissues from current and former smokers compared with never smokers (e -Fig 2) . TREM2, TREM2/CD68, or TREM2/TREM1 expression was not associated with clinical symptoms, such as wheezing or cough productive of phlegm, in cohort 2 (data not shown). 
Discussion
Our previous work with a mouse model showed that Trem-2 (but not Trem-1) expression is a key component of the type 2 immune response that drives chronic airway disease in a mouse model of this process. 6, 7, 18 The present study shows their relevance to humans who have COPD and builds on these observations. First, TREM2 mRNA and TREM-2 protein expression were both significantly increased compared with corresponding levels of TREM1 mRNA TREM2/GAPDH (copy#) TREM1/CD68 (copy#) TREM2/CD68 (copy#) P < .001 P = .022 P = .022 Figure 3 -A-F, TREM2 messenger (mRNA) expression is increased in COPD in cohort 2. A, Levels of TREM1 and TREM2 mRNA (normalized to GAPDH) in lung tissues from patients with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage IV COPD and never smokers. B, Levels of TREM1 and TREM2 mRNA normalized to CD68 mRNA level in lung tissues from patients with GOLD stage IV COPD and never smokers. D, Levels of TREM2/TREM1 mRNA ratio in patients with GOLD stage IV COPD and never smokers. E, Analysis of TREM2/TREM1 mRNA ratio in lung tissue from all subjects in cohort 2 using the receiver operating characteristic curve to compare values in patients with no COPD or GOLD stage I or II COPD vs GOLD stage III or IV COPD. F, Analysis of TREM2/TREM1 mRNA ratio vs FEV 1 percent predicted or FEV 1 /FVC in all subjects from cohort 2. In (A-F), each dot represents the value for a single subject. Boxes demonstrate the median (horizontal line) and 25th to 75th percentiles, and whiskers represent the range. r values are from Spearman correlation, and P values are from Mann-Whitney U test. CD68 expression was not significantly different between never smokers and GOLD stage IV COPD in (B), and did not correlate with FEV 1 percent predicted or FEV 1 /FVC in (F). AUC ¼ area under the curve; NS ¼ not significant.
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and TREM-1 protein in lung tissues from patients who had severe COPD compared with those without COPD. Second, TREM2 mRNA expression was linked closely with DAP12 and CD68 mRNA levels as markers of macrophages and with CD206 and CHIT1 as markers of M2 macrophages, and TREM-2 protein expression was found in CD68-, CD14-, and CCR2-expressing monocyte/macrophage populations in lung tissues. Third, a disproportionate increase in TREM2/ TREM1 mRNA expression correlated significantly with a decline in FEV 1 or FEV 1 /FVC in those with COPD, similar to the association of CHIT1 levels in lung tissues, with FEV 1 and FEV 1 /FVC. Together, these results indicate that TREM-2 expression tracks with a type 2 (M2) macrophage response in COPD lung tissues that includes increased expression of epithelial IL-33, immune cell production of IL-13, and M2 macrophage activation that we and others have reported. 6, 7, 9, 10, 18 Given the role for Trem-2 in amplifying the type 2 immune response and consequent airway disease in a mouse model, these results suggest that TREM-2 may participate in the pathogenesis of COPD in humans, and it may even provide a new target in the management of this and other diseases marked by type 2 inflammation and M2 macrophage activation.
Our approach is distinct from the few previous studies of TREM expression in COPD. Earlier studies focused on TREM-1 levels in serum and on TREM-2 levels in macrophages obtained by BAL. 22, 25 Instead, we examined both TREM-1 and TREM-2 directly in lung tissues where disease occurs and the highest levels of TREM-2 expression should be found, based on an experimental model of mouse airway disease. 18 We detected increases in TREM2 mRNA expression in current smokers, consistent with the earlier evidence for smoke-induced increases in TREM-2 levels in macrophages from BAL and macrophage cell lines in culture. 25, 26 By extending our experimental results from the mouse model, it appears that both viral infection and tobacco smoke exposure can contribute to M2 macrophage activation marked by TREM-2 expression in the pathogenesis of severe COPD.
The present results also provide insight into the role of TREM-1 expression in COPD. Several studies have suggested that TREM-1 is increased in COPD based on serum levels of soluble TREM-1. [22] [23] [24] However, we found barely detectable levels of TREM-1 protein in the lungs of patients with COPD by ELISA and immunostaining. In fact, the levels of TREM1 mRNA were the same or lower in lung tissue from patients with GOLD stage IV COPD compared with never smokers. The highest levels of TREM1 were found in current smokers with early stages of disease. Lower levels of TREM1 were found in former smokers compared with current smokers; however, the range of TREM1 expression was similar between these groups (Fig 2A) . These results were somewhat surprising because neutrophils can also express TREM-1, 13 and neutrophil infiltration is common in COPD lung tissues. 29 Nevertheless, our results indicate that the levels of TREM2 mRNA are higher than TREM1 in lungs from former and current smokers, and the ratio of TREM2/TREM1 expression increases disproportionately with greater disease severity. This imbalance is consistent with a shift from an M1-like inflammatory response in earlier stages of COPD to an M2-like response found in the most advanced stages of disease. Further studies are needed using lung tissues from patients with less severe forms of COPD, including current and former smokers, to better define the nature of M1 and M2 macrophages in these earlier stages of disease.
Our study provides a basis for further studies of TREM function in chronic airway disease. Experimental work suggests that the cleaved form of TREM-1 may function as a decoy receptor to downmodulate inflammation, 30 particularly in the setting of acute bacterial infections.
14 By contrast, we recently found that both the full-length and soluble forms of Trem-2 contribute to macrophage survival and differentiation in the setting of viral infection in a mouse model. 18 . Acute infection leads to an increase in surface Trem-2 expression that is augmented by IL-13. Chronic lung inflammation mediated by IL-13, in turn, contributes to the cleavage and formation of soluble Trem-2 that helps to promote M2 macrophage survival and perpetuate disease. In humans with COPD, tobacco smoke, respiratory viruses, and other inhaled toxins may activate the analogous IL-33/IL-13/TREM-2 pathway leading to mucus production, M2 macrophage activation, and alveolar destruction. Excess soluble TREM-2 may account for the differences in total TREM-2 protein found in COPD lungs compared with non-COPD lungs in Figure 2A , in contrast with the similar levels of surface-bound TREM-2 detected by flow cytometry in Figure 2C . In CNS diseases, increased levels of soluble form TREM-2 may help to regulate inflammation 20 and decreased TREM-2 function may contribute to neurodegeneration. 18, 21, 31 By extension, surface-bound and soluble forms of TREM-2 (and TREM-1) may contribute to the development and progression of COPD, and perhaps some forms of asthma and the closely related asthma-COPD overlap syndrome that were not included here. The present work provides the first indication that TREM-2 may be a useful biomarker, contributory factor, and therapeutic target in lung diseases like COPD.
Conclusions TREM-2 expression is increased in lung macrophages in COPD, particularly in comparison with TREM-1 expression. Therefore, TREM-2 levels and TREM-2/ TREM-1 ratio may be markers of M2 macrophage activation and a guide to diagnosis and treatment directed against the type 2 immune response in patients with COPD.
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